Fibroblast growth factor 23 concentrations in healthy term infants during the early postpartum period

Bone

Volumn 47, Issue 2, 2010, Pages 256-262

  Takaiwa, Masanori ^a,b   Aya, Kunihiko ^a   Miyai, Takayuki ^a   Hasegawa, Kosei ^a   Yokoyama, Motofumi ^b   Kondo, Youichi ^b   Kodani, Nobuyuki ^b   Seino, Yoshiki ^c   Tanaka, Hiroyuki ^d   Morishima, Tsuneo ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b MATSUYAMA RED CROSS HOSPITAL   (Japan)

^c OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^d OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

Author keywords

1,25 dihydroxy vitamin D; Calcium; Fibroblast growth factor 23; Intact PTH; Phosphate; Term infants

Indexed keywords

CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; INOSITOL PHOSPHATE; 1,25-DIHYDROXYVITAMIN D; CALCIUM; FIBROBLAST GROWTH FACTOR; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

ADULT; ARTICLE; BLOOD SAMPLING; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOPRECIPITATION; INFANT; MALE; NORMAL HUMAN; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PUERPERIUM; UMBILICAL CORD BLOOD; VITAMIN D METABOLISM; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; HEALTH; MOLECULAR WEIGHT; NEWBORN; TERM BIRTH;

CALCIUM; FEMALE; FIBROBLAST GROWTH FACTORS; HEALTH; HUMANS; IMMUNOPRECIPITATION; INFANT, NEWBORN; MALE; MOLECULAR WEIGHT; PARATHYROID HORMONE; PHOSPHATES; POSTPARTUM PERIOD; TERM BIRTH; VITAMIN D;

EID: 77955983893     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.05.024     Document Type: Article

References (38)

1. Sitara D., Razzaque M.S., St-Arnaud R., Huang W., Taguchi T., Erben R.G., et al. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol 2006, 169:2161-2170.
2. Liu S., Zhou J., Tang W., Jiang X., Rowe D.W., Quarles L.D. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006, 291:E38-E49.
3. Ubaidus S., Li M., Sultana S., de Freitas P.H., Oda K., Maeda T., et al. FGF23 is mainly synthesized by osteocytes in the regularly distributed osteocytic lacunar canalicular system established after physiological bone remodeling. J Electron Microsc (Tokyo) 2009.
4. Topaz O., Shurman D.L., Bergman R., Indelman M., Ratajczak P., Mizrachi M., et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 2004, 36:579-581.
5. Kato K., Jeanneau C., Tarp M.A., Benet-Pages A., Lorenz-Depiereux B., Bennett E.P., et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 2006, 281:18370-18377.
6. Burnett S.M., Gunawardene S.C., Bringhurst F.R., Juppner H., Lee H., Finkelstein J.S. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006, 21:1187-1196.
7. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770-774.
8. Kurosu H., Ogawa Y., Miyoshi M., Yamamoto M., Nandi A., Rosenblatt K.P., et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006, 281:6120-6123.
9. Gattineni J., Bates C., Twombley K., Dwarakanath V., Robinson M.L., Goetz R., et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 2009, 297:F282-F291.
10. Farrow E.G., Davis S.I., Summers L.J., White K.E. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 2009, 20:955-960.
11. Larsson T., Marsell R., Schipani E., Ohlsson C., Ljunggren O., Tenenhouse H.S., et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004, 145:3087-3094.
12. Shimada T., Hasegawa H., Yamazaki Y., Muto T., Hino R., Takeuchi Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004, 19:429-435.
13. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000, 26:345-348.
14. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001, 98:6500-6505.
15. Shimada T., Muto T., Urakawa I., Yoneya T., Yamazaki Y., Okawa K., et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002, 143:3179-3182.
16. Benet-Pages A., Orlik P., Strom T.M., Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005, 14:385-390.
17. Garringer H.J., Fisher C., Larsson T.E., Davis S.I., Koller D.L., Cullen M.J., et al. The role of mutant UDP-N-acetyl-alpha-d-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. J Clin Endocrinol Metab 2006, 91:4037-4042.
18. Larsson T., Yu X., Davis S.I., Draman M.S., Mooney S.D., Cullen M.J., et al. A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 2005, 90:2424-2427.
19. Yamazaki Y., Okazaki R., Shibata M., Hasegawa Y., Satoh K., Tajima T., et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002, 87:4957-4960.
20. Durham B.H., Joseph F., Bailey L.M., Fraser W.D. The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays. Ann Clin Biochem 2007, 44:463-466.
21. Loughead J.L., Mimouni F., Tsang R.C. Serum ionized calcium concentrations in normal neonates. Am J Dis Child 1988, 142:516-518.
22. Kovacs C.S., Kronenberg H.M. Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. Endocr Rev 1997, 18:832-872.
23. Jonsson K.B., Zahradnik R., Larsson T., White K.E., Sugimoto T., Imanishi Y., et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003, 348:1656-1663.
24. Yamashita T. Structural and biochemical properties of fibroblast growth factor 23. Ther Apher Dial 2005, 9:313-318.
25. Khosravi A., Cutler C.M., Kelly M.H., Chang R., Royal R.E., Sherry R.M., et al. Determination of the elimination half-life of fibroblast growth factor-23. J Clin Endocrinol Metab 2007, 92:2374-2377.
26. Burnett-Bowie S.A., Henao M.P., Dere M.E., Lee H., Leder B.Z. Effects of hPTH(1-34) infusion on circulating serum phosphate, 1, 25-dihydroxyvitamin D and FGF23 levels in healthy men. J Bone Miner Res 2009.
27. Yamashita H., Yamazaki Y., Hasegawa H., Yamashita T., Fukumoto S., Shigematsu T., et al. Fibroblast growth factor-23 (FGF23) in patients with transient hypoparathyroidism: its important role in serum phosphate regulation. Endocr J 2007, 54:465-470.
28. Kobayashi K., Imanishi Y., Miyauchi A., Onoda N., Kawata T., Tahara H., et al. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol 2006, 154:93-99.
29. Benet-Pages A., Lorenz-Depiereux B., Zischka H., White K.E., Econs M.J., Strom T.M. FGF23 is processed by proprotein convertases but not by PHEX. Bone 2004, 35:455-462.
30. Frishberg Y., Ito N., Rinat C., Yamazaki Y., Feinstein S., Urakawa I., et al. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res 2007, 22:235-242.
31. Ichikawa S., Imel E.A., Sorenson A.H., Severe R., Knudson P., Harris G.J., et al. Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene. J Clin Endocrinol Metab 2006, 91:4472-4475.
32. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004, 113:561-568.
33. Tsujikawa H., Kurotaki Y., Fujimori T., Fukuda K., Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003, 17:2393-2403.
34. Yoshiko Y., Wang H., Minamizaki T., Ijuin C., Yamamoto R., Suemune S., et al. Mineralized tissue cells are a principal source of FGF23. Bone 2007, 40:1565-1573.
35. Cormier S., Leroy C., Delezoide A.L., Silve C. Expression of fibroblast growth factors 18 and 23 during human embryonic and fetal development. Gene Expr Patterns 2005, 5:569-573.
36. Zhong W., Wang Q.T., Sun T., Wang F., Liu J., Leach R., et al. FGF ligand family mRNA expression profile for mouse preimplantation embryos, early gestation human placenta, and mouse trophoblast stem cells. Mol Reprod Dev 2006, 73:540-550.
37. White K.E., Carn G., Lorenz-Depiereux B., Benet-Pages A., Strom T.M., Econs M.J. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001, 60:2079-2086.
38. Chefetz I., Kohno K., Izumi H., Uitto J., Richard G., Sprecher E. GALNT3, a gene associated with hyperphosphatemic familial tumoral calcinosis, is transcriptionally regulated by extracellular phosphate and modulates matrix metalloproteinase activity. Biochim Biophys Acta 2009, 1792:61-67.